Last month, we launched our newest publication, Life Science Compliance Update. Each issue delivers in-depth analysis of important compliance issues for both pharmaceutical and device companies and those who serve that industry, with input from top compliance officers and healthcare attorneys across the industry. We encourage you to download the sample issue and consider subscribing.
*** Policy and Medicine readers are entitled to a 15% discount on subscriptions. The discount code is: CHARTER15 ***
Available now, the May 2015 issue of Life Science Compliance Update provides a thorough look into the Food and Drug Administration’s promotional oversight and recent enforcement activity. You’ll find insight into FDA’s priorities, a “Tweet-sized” look at the Agency’s social media guidances, and an explanation of new Untitled and Warning Letters from the Office of Prescription Drug Promotion.
This issue also provides an analysis of uncharted regulatory territory for the FDA. Our featured article, “Keeping an Eye on Your Supply: A Step-By-Step Guide to Track and Trace,” written by Nicodemo Fiorentino, JD, Senior Advisor, Research & Compliance at G&M Health, LLC, offers an easy-to-understand guide to important provisions of the Drug Supply Chain and Security Act. We also provide a snapshot of where the FDA stands with its regulation of biosimilars, having approved the first biosimilar product in the U.S. earlier this year.
Finally, the May issue offers a look at a new compliance guide out of the Office of Inspector General—always an important Agency for the industry to pay attention to.
The May 2015 issue of Life Science Compliance Update provides the life sciences industry with important news and analysis, covering:
* OPDP Enforcement Letters and Areas of Interest
* A Step-By-Step Guide to Track and Trace
* Social Media Guidance and Updates
* The Current State of Biosimilar Regulation
* Highlights of FDA’s Past Year
* OIG’s New Compliance Guide for Boards of Directors